The Boston subcohort will support an ancillary study of other health outcomes, including diabetes and glucose tolerance, hypertension, cognitive function, depression, osteoporosis and fracture, physical performance and falls, respiratory function, infections, and rheumatoid arthritis and other autoimmune disorders.